Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HELP
HELP logo

HELP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cybin Inc (HELP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.510
1 Day change
-0.66%
52 Week Range
8.970
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cybin Inc (HELP) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. The technical indicators are bearish, options sentiment is neutral to slightly positive, and there are no significant news or catalysts in the near term. Additionally, the company's financials show significant losses, and there is no recent congress trading data or Intellectia Proprietary Trading Signals to support a buy decision.

Technical Analysis

The technical indicators are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 32.446, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 4.641, with resistance at 5.149.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options data indicates a low put-call ratio, suggesting a slightly bullish sentiment. However, implied volatility is high at 118.6, with an IV percentile of 70, indicating elevated risk.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
3

Positive Catalysts

  • These could significantly boost the stock in the long term.

Neutral/Negative Catalysts

  • No significant news or events in the short term. The company's financials show substantial losses with no revenue growth. Technical indicators are bearish, and there is no recent congress trading data or influential insider activity.

Financial Performance

In Q3 2026, the company reported a net income loss of -$42.67M, which improved YoY by 465.96%. EPS also improved to -1, up 163.16% YoY. However, revenue remains at 0, with no growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Jefferies analyst Andrew Tsai initiated a Buy rating with a $22 price target, citing potential catalysts in 2026, including Phase III success for HLP003 and Phase II data for HLP004. However, these are long-term catalysts and not immediately actionable.

Wall Street analysts forecast HELP stock price to rise
6 Analyst Rating
Wall Street analysts forecast HELP stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.540
sliders
Low
22
Averages
41.17
High
55
Current: 4.540
sliders
Low
22
Averages
41.17
High
55
Jefferies
Andrew Tsai
initiated
$22
AI Analysis
2026-02-01
Reason
Jefferies
Andrew Tsai
Price Target
$22
AI Analysis
2026-02-01
initiated
Reason
Jefferies analyst Andrew Tsai initiated coverage of Helus Pharma with a Buy rating and $22 price target. The firm sees the stock potentially moving "significantly higher" into three catalysts in 2026. Helus' lead asset HLP003 has a 60% probability of success of succeeding in a Phase III in adjunct major depressive disorder, which could result in a 100%-200% share rally, the analyst tells investors in a research note. Jefferies adds that HLP004 is a short-duration psychedelic that has "de-risking" Phase II data in Q1. It also believes Helus finding a CEO is another catalyst.

People Also Watch